Lexicon Pharmaceuticals
LXRX
112 hedge funds and large institutions have $206M invested in Lexicon Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 21 closing their positions.
52% more call options, than puts
Call options by funds: $441K | Put options by funds: $291K
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 123 → 112 (-11)
12.54% less ownership
Funds ownership: 89.62% → 77.08% (-13%)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
53% less capital invested
Capital invested by funds: $438M → $206M (-$232M)
Top Buyers
| 1 |
Millennium Management
New York
|
+$2.2M |
| 2 |
Two Sigma Investments
New York
|
+$909K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$660K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$501K |
| 5 |
BlackRock
New York
|
+$484K |
Top Sellers
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.16M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.66M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$1.2M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$1.15M |
| 5 |
Axa
Paris,
France
|
-$816K |
LXRX Hedge Fund Activity: Q3 2023 in Review
112 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2023, worth a combined $206M — down 53% from $438M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of LXRX and 11 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 44 added.
The largest buyer was Millennium Management, adding an estimated $2.2M. The largest seller was Alyeska Investment Group, cutting an estimated $2.16M.
- 112 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2023, down from 123 in Q2 2023.
- Funds reported $206M of Lexicon Pharmaceuticals stock for Q3 2023, down 53% quarter-over-quarter.
- 11 funds opened new Lexicon Pharmaceuticals positions in Q3 2023 and 21 closed out, a net change of -10 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2023 was Millennium Management, an estimated $2.2M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2023 was Alyeska Investment Group, an estimated $2.16M sold.
Based on aggregated 13F filings for Q3 2023.